Following in vitro exposure of CF monocytes to ivacaftor/lumacaftor or ivacaftor/tezacaftor, a significant reduction in IL-18 was reported, whereas IL-1b was only reduced with ivacaftor/tezacaftor. Here, IL1B is linked to cystic fibrosis.